Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treosulfan may become standard in allo-HCT for AML/MDS

Publish date:: February 25, 2019

Key clinical point: A treosulfan-based conditioning regimen could become a standard prior to allogeneic transplant in elderly or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Major finding: Event-free survival at 2 years was 65.7% and 51.2%, respectively, for the treosulfan- and busulfan-based conditioning regimens (P = .0000001).

Study details: Final analysis of the randomized phase 3 MC-FludT.14/L study, including 551 patients with AML or MDS.

Disclosures: Dr. Beelen reported honoraria, travel support, and trial documentation support provided by medac GmbH, which sponsored the trial.

Citation:

Beelen DW et al. TCT 2019, Abstract 4.

This Week's Must Reads

High RDW Linked to Poor Survival in DLBCL,

Prophylaxis Doesn’t Seem to Prevent CNS Relapse in DLBCL,

R-DHAOx May Be ‘Attractive’ Salvage Option For Rel/Ref DLBCL,

Pretransplant TLG Associated With Survival in DLBCL,

Rituximab Appears to Lower Risk of Late Relapse in DLBCL,

Must Reads in AML

Treosulfan may become standard in allo-HCT for AML/MDS,

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML,

IDH-mutated AML: First-line IDH inhibitors, chemo may up remission, Stein EM et al. ASH 2018, Abstract 560

Rapid genomic results possible, Beat AML trial suggests, Burd A et al. ASH 2018, Abstract 559

Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774